Rimonabant, aswell accepted as SR141716, was the aboriginal careful axial cannabinoid (CB) receptor changed agonist (Ki = 1.8 nM) to be developed as an appetence suppressant, anti-obesity drug. It is broadly acclimated as a apparatus to investigate CB receptor backdrop and the mechanisms by which CB agonists apply their pharmacological effects. In rodent models and analytic trials, rimonabant finer induces lipolysis, reduces hepatomegaly, decreases physique weight, and improves dyslipidemia by abbreviation triglyceride, chargeless blubbery acid, and absolute cholesterol levels and by accretion HDL/LDL ratios. However, rimonabant reportedly produces adverse psychiatric and acoustic furnishings (e.g., abasement or anxiety) and accordingly is not accustomed by the FDA for use as a weight ascendancy medication. Rimonabant elicits antiproliferative and immunomodulatory furnishings (e.g., corpuscle aeon arrest, added announcement of IκB and phosphorylated Akt, and decreased announcement of NF-κB, phosphorylated ERK1/2, COX-2, and iNOS) in vitro.
from:Acridine Raw Material
